uniQure (NASDAQ:QURE) Upgraded at Mizuho

Mizuho upgraded shares of uniQure (NASDAQ:QURE) from a neutral rating to an outperform rating in a research note issued to investors on Thursday, Marketbeat.com reports. The firm currently has $30.00 price target on the biotechnology company’s stock.

A number of other equities analysts also recently commented on the company. Cantor Fitzgerald set a $47.00 price objective on uniQure in a report on Wednesday, July 30th. Guggenheim restated a “buy” rating and issued a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. Chardan Capital lowered their price target on uniQure from $38.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, July 29th. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of uniQure in a report on Thursday, May 29th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.45.

uniQure Price Performance

Shares of QURE opened at $16.18 on Thursday. The business’s 50-day moving average is $14.62 and its 200-day moving average is $13.63. uniQure has a fifty-two week low of $4.45 and a fifty-two week high of $19.18. The company has a market capitalization of $887.80 million, a price-to-earnings ratio of -4.13 and a beta of 0.11. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. The firm had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. Equities research analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Insider Activity at uniQure

In other news, Director Rachelle Suzanne Jacques sold 2,112 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the sale, the director directly owned 28,346 shares of the company’s stock, valued at approximately $409,599.70. This represents a 6.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jeannette Potts sold 4,670 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $15.14, for a total value of $70,703.80. Following the completion of the sale, the insider directly owned 115,073 shares of the company’s stock, valued at $1,742,205.22. This represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,144 shares of company stock valued at $322,426. 4.79% of the stock is owned by company insiders.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently modified their holdings of QURE. Tower Research Capital LLC TRC boosted its position in shares of uniQure by 358.0% in the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 5,538 shares during the period. Mraz Amerine & Associates Inc. bought a new stake in shares of uniQure in the first quarter valued at approximately $106,000. KLP Kapitalforvaltning AS bought a new stake in shares of uniQure in the second quarter valued at approximately $117,000. Teacher Retirement System of Texas bought a new stake in shares of uniQure in the second quarter valued at approximately $151,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of uniQure in the first quarter valued at approximately $152,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.